Alport Syndrome - Epidemiology Forecast - 2034

Alport Syndrome - Epidemiology Forecast - 2034



Key Highlights

Alport syndrome is an inherited disease, with X-linked being the most common type of it, and accounts for approximately 80% of the total cases.

In the absence of intervention, approximately 90% of males experience kidney failure by the age of 40, whereas females less commonly and more gradually progress to kidney failure.

The majority of alport syndrome patients remain undiagnosed due to the asymptomatic nature of the disease and misdiagnosis.

The total number of prevalent cases of alport syndrome in the US were ~67,900 in 2023.

Alport syndrome affects both men and women in the United States with minimal disparity, although men are slightly more impacted than women.

DelveInsight's “Alport Syndrome Epidemiology Forecast – 2034” report delivers an in-depth understanding of alport syndrome, historical and forecasted epidemiology trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Alport Syndrome Understanding and Treatment Algorithm

Alport Syndrome Overview and Diagnosis

Alport syndrome is a rare genetic disorder characterized by abnormalities of the inner ear and the eye. The disease is caused by an inherited defect in type IV collagen, a structural material needed for the normal function of different body parts. Alport syndrome can present itself in many forms. This includes X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), and autosomal dominant Alport syndrome (ADAS). Clinically, it is associated with microscopic hematuria, followed by proteinuria and chronic renal insufficiency with end-stage renal disease in young adults.

Diagnosis of Alport syndrome is much more likely when there is a family history of Alport syndrome, early hearing loss, hematuria, or kidney failure with unknown cause. Suspicion of the disease is generally heightened when hearing loss is present. Diagnosis can be confirmed by examination of kidney biopsies, where collagen expression and structural changes to the GBM can be observed by immunofluorescence and electron microscopy, respectively. In the case of X-linked Alport syndrome, immunofluorescence microscopy may be employed on skin biopsies to assess the presence of the type IV collagen a-5 chain. Diagnosis is increasingly confirmed by genetic testing.

Further details related to country-based variations in diagnosis are provided in the report…

Alport Syndrome Epidemiology

The Alport Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

The total number of prevalent cases of alport syndrome in the 7MM were ~159,000 in 2023.

Alport syndrome is more prevalent in adult population with ~86% contribution in the 7MM, while pediatric population accounted for ~14% cases.

The X-linked alport syndrome (XLAS) is most prevalent subtype of alport syndrome with around 11,500 cases in 2023 in the US while autosomal dominant alport syndrome (ADAS) being the least prevalent subtype of alport syndrome.

In EU4 region, the total prevalent cases were the highest in Germany, with nearly 17,000 cases in 2023, while Spain had the least number of cases in 2023.

Scope of the Report

The report covers a segment of key events, an executive summary, and a descriptive overview of alport syndrome, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.

A detailed review of the alport syndrome epidemiology, detailed assumptions, and rationale behind our approach is included in the report.

A detailed review of current challenges in establishing the diagnosis.

Alport Syndrome Report Insights

Patient Population

Patient population by gender, type, and age

Country-wise Epidemiology Distribution

Alport Syndrome Report Key Strengths

11 Years Forecast

7MM Coverage

Alport Syndrome Epidemiology Segmentation

Alport Syndrome Report Assessment

Epidemiology Segmentation

Current Diagnostic Practices

FAQs

What are the disease risk and burdens and of alport syndrome? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to alport syndrome?

What is the historical and forecasted alport syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Which age group is the largest contributor in patients affected with alport syndrome?

Which subtype is more prevalent among all the subtypes?

Why the diagnosed prevalent cases remain very low in the 7MM?

Reasons to buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand Key Opinion Leaders’ perspectives around the epidemiology distribution and country-wise variations.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.


1. Key Insights
2. Report Introduction
3. Executive Summary Of Alport Syndrome
4. Alport Syndrome Epidememiology Overview At A Glance
4.1. Patient Share (%) Distribution In 2020
4.2. Patient Share (%) Distribution In 2034
5. Epidemiology Methodology
6. Disease Background And Overview
6.1. Introduction
6.2. Types Of Alport Syndrome
6.3. Signs And Symptoms
6.3.1. Renal Manifestations
6.3.2. Hearing Impairment
6.3.3. Ocular Manifestations
6.3.4. Leiomyomatosis
6.4. Causes Of Alport Syndrome
6.5. Pathophysiology Of Alport Syndrome
6.6. Diagnosis Of Alport Syndrome
6.6.1. Clinical Diagnosis
6.6.2. Genetic Diagnosis
6.6.3. Other Tests
6.7. Prognosis
6.8. Differential Diagnosis
6.9. Prognosis
7. Epidemiology And Patient Population
7.1. Key Findings
7.2. Assumptions And Rationale
7.3. Total Prevalent Cases Of Alport Syndrome In The 7mm
7.4. Total Diagnosed Prevalent Cases Of Alport Syndrome In The 7mm
10.5. The United States
7.5.1. Total Prevalent Cases Of Alport Syndrome In The United States
7.5.2. Total Diagnosed Prevalent Cases Of Alport Syndrome In The United States
7.5.3. Gender-specific Cases Of Alport Syndrome In The United States
7.5.4. Age-specific Cases Of Alport Syndrome In The United States
7.5.5. Type-specific Cases Of Alport Syndrome In The United States
7.6. Eu4 And The Uk
7.6.1. Total Prevalent Cases Of Alport Syndrome In Eu4 And The Uk
7.6.2. Total Diagnosed Prevalent Cases Of Alport Syndrome In Eu4 And The Uk
7.6.3. Gender-specific Cases Of Alport Syndrome In Eu4 And The Uk
7.6.4. Age-specific Cases Of Alport Syndrome In Eu4 And The Uk
7.6.5. Type-specific Cases Of Alport Syndrome In Eu4 And The Uk
7.7. Japan
7.7.1. Total Prevalent Cases Of Alport Syndrome In Japan
7.7.2. Total Diagnosed Prevalent Cases Of Alport Syndrome In Japan
7.7.3. Gender-specific Cases Of Alport Syndrome In Japan
7.7.4. Age-specific Cases Of Alport Syndrome In Japan
7.7.5. Type-specific Cases Of Alport Syndrome In Japan
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. Delveinsight Capabilities
10. Disclaimer
11. About Delveinsight

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings